|

liposomal irinotecan Clinical Trials

10 actively recruiting trials across 4 locations

No change since May 2026

Also known as: (Onivyde®), Nal-IRI, New Neoadjuvant Treatment Approach, irinotecan liposome, nal-IRI

Pipeline

Phase 1: 2Phase 2: 5Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Hebei Medical University Fourth Hospital2
  • University of Wisconsin, Madison1
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
  • The First Affiliated Hospital with Nanjing Medical University1
  • St. Jude Children's Research Hospital1

Indications

  • Cancer10
  • Rectal Cancer2
  • Osteosarcoma Metastatic1
  • Rectal Cancer, Adenocarcinoma1
  • Metastatic Pancreatic Adenocarcinoma1

Other6 trials

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/2
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Phase 2
NALIRIFOX as Induction Therapy in LAPC
Phase 2
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Phase 2
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
N/A
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Phase 1

Duarte, California1 trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1

Fullerton, California1 trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton

Phase 3

Palo Alto, California1 trial

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Stanford University

Phase 2

Madison, Wisconsin1 trial

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

University of Wisconsin Carbone Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.